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monitored for acute toxicity using the Common Toxicity 
Criteria, version 3.0 and late toxicity using the RTOG/EORTC. 
 
Results: 3° (9/27) hematologic toxicity, principally 
neutropenia (9/27) and thrombocytopenia (2/27), occurs late 
cycles. No grade 4 toxicity occurred. 2 patients (ages: 78~79) 
finished 200 mg nimotuzumab weekly for six cycles with 1° 
hematologic. Others finished 5 ~ 6 cycles chemotherapy. All 
of patients finished radiotherapy in 7 ~8 weeks. The median 
follow-up was 9.5 months (3 ~ 22). At 4 months, 24 patients 
had attained complete response (23 CR, 1 pCR), 3 patients 
had achieved partial response (PR). 2 of 3 patients who had 
PR appeared local recurrent at 8 months and 9 months 
respectively. Local control rates were 92.6 %（25/27）. All of 
patients are still survive. 1 patient had haemorrhagic 
radiation proctitis at 7 months. 
 
Conclusion: Combination nimotuzumab 200 mg and DDP 40 
mg/m2 weekly for six cycles concurrently with intensity-
modulated radiotherapy can be safely administered in 
Chinese women. Primary result showed a good clinical 
outcome. We need continue follow-up. Further development 
to determine if the combination will help yield a survival 
benefit. 
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Purpose or Objective: stereotactic body radiotherapy (SBRT) 
has emerged as an effective treatment for localized prostate 
cancer. However, prostate-specific antigen (PSA) kinetics 
after SBRT has not been well characterized. The objective of 
the current study is to analyze the rate of PSA decline and 
PSA nadir following hypofractonated SBRT in low- and 
intermediate-risk prostate cancer. 
 
Material and Methods: From 2008 to 2014, thirty-six patients 
newly diagnosed, low- and intermediate-risk (NCCN 
definition) prostate cancer were treated with SBRT using 
Cyberknife. Total dose of 36.25 Gy in 5 fractions of 7.25 Gy 
were administered. No one received androgen deprivation 
therapy (ADT). PSA nadir and rate of change in PSA (slope) 
were calculated and compared. 
 
Results: With a median follow-up of 52 months (range, 13-
71), the median rates of decline of PSA were -0.359, -0.199 
and -0.127 ng/mL/month, respectively, for durations of 1, 2 
and 3 years after radiotherapy, respectively. The decline of 
PSA was maximal in the first year and continuously decreased 
for durations of 2 and 3 year. The median PSA nadir was 0.27 
ng/mL after a median 33 months. 5-year biochemical failure 
(BCF)-free survival was 100% for low- and intermediate-risk 
patients. 
 
Conclusion: In this report of low- and intermediate-risk 
prostate cancer, continuous decrease of PSA level for 
duration 1, 2 and 3 year following SBRT using Cyberknife 
resulted in lower PSA nadir. Also, SBRT leaded to long-term 
favorable BCF-free survival in low- and intermediate-risk 
prostate cancer. 
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Purpose or Objective: Hypofractionated stereotactic body 
radiotherapy (SBRT) has emerged as an effective treatment 
for localized prostate cancer. However, prostate specific 
antigen (PSA) kinetics after SBRT has not been well 
characterized. The purpose of this study was to compare the 
PSA kinetics between SBRT using Cyberknife and 
conventionally fractionated external beam radiotherapy (CF-
EBRT) in low- and intermediate-risk prostate cancer. 
 
Material and Methods: A total of sixty-nine patients with 
low-and intermediate-risk prostate cancer were enrolled. 34 
patients were treated with SBRT (36.25Gy in 5 fractions) 
using Cyberknife and 35 patients treated with CF-EBRT (45 Gy 
whole pelvis EBRT and boost of 25.2-30.6 Gy in 1.8 Gy 
fractions). PSA nadir and rate of PSA decline in PSA (slope) 
were calculated and compared. 
 
Results: With a median follow-up of 53.6 months (range, 14-
74), the median PSA nadir and median slope for SBRT were 
0.23 ng/mL and -0.430, -0.199, -0.127 and -0.094 
ng/mL/month, respectively, for durations of 1, 2, 3 and 4 
years following radiotherapy. Similarly, for CF-EBRT, the 
median PSA nadir and median slopes were 0.37 ng/mL and -
0.529, -0.138, -0.109 and -0.056 ng/mL/month, respectively. 
The slope of CF-EBRT was significantly different with a 
greater median rate of change for 1 year post radiotherapy 
than that of SBRT (p=0.018). Contrastively, the slopes of 
SBRT for duration for 2, 3 and 4 year tended to be 
continuously greater than that of CF-EBRT (p=0.028, p=0.058 
and p=0.128, respectively). The significantly lower PSA nadir 
was observed in SBRT (median nadir 0.23 ng/mL) compared 
with CF-EBRT (median nadir 0.37ng/mL) (p=0.011). 5-year 
biochemical failure (BCF) free survival were 100% for SBRT 
and 80.8% for CF-EBRT (p=0.031). 
 
Conclusion: Patients treated with SBRT using Cyberknife 
experienced a lower PSA nadir and tended to be continuously 
greater rate of decline of PSA for duration 2, 3 and 4 years 
than CF-EBRT. The improved PSA kinetics of SBRT over CF-
EBRT leaded to favorable BCF-free survival. Further studies 
with more patients and longer follow-up duration are 
required. 
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Purpose or Objective: to analyze predictors of genitourinary 
(GU) toxicity in a cohort of prostate cancer (PC) patients 
treated with moderate hypofractionation and simultaneous 
integrated boost (SIB) using volumetric modulated arc 
therapy (VMAT) technique. 
 
Material and Methods: Clinical and dosimetric data were 
prospectively collected and retrospectively analyzed. 
Patients were stratified into low (43%), intermediate (30%) 
and high-risk (27%) groups. Target volumes (expanded to 
define the planning volumes (PTV)) were clinical target 
volume (CTV) 1: prostate; CTV2: CTV1 + seminal vesicles; 
CTV3: CTV2 + pelvic nodes. Low-risk patients received 73.5 
Gy to PTV1; intermediate-risk 73.5 Gy to PTV1 and 60 Gy to 
PTV2; high-risk 73.5 Gy to PTV1, 60 Gy to PTV2, and 54 Gy to 
PTV3. All treatments were in 30 fractions. Androgen 
deprivation therapy (ADT) was prescribed upfront in 
intermediate and high risk patients. Rectal and GU toxicities 
were scored according to Common Terminology Criteria for 
Adverse Events v4.0 scoring system. 
 
Results: From January 2012, 60 patients with localized PC 
were recruited in an internal protocol of moderate 
hypofractionation SIB schedule using VMAT technique with 
definitive intent. The median follow-up was 24 months (range 
10 - 36 months). GU acute toxicity was recorded as follow: 
G0 = 16/60 (27%), G1 = 18/60 (30%); G2= 26/60 (43%); no 
case of toxicity ≥ G3 was registered. GU late toxicity was 
recorded as follow: G0 = 20/60 (34%); G1 = 29/60 (48%); G2 = 
11/56 (19%); no case of toxicity ≥ G3 was registered. The risk 
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of acute G2 GU toxicity was about 3 times if the prostate 
volume is ≥ 80 cc (p -value 0.004; 95% CI: 1.05 - 9.5). In the 
adjusted prediction model using the logistic regression, the 
probability of acute G2 GU toxicity was about 60% with the 
same prostate volume cut-off (p-value 0.001; 95% CI: 0.13 - 
0.46), with an attitude to develop a moderate toxicity in the 
first 3 weeks from the beginning of treatment. In the late 
setting, a trend to significance (p=0.076) to develop an acute 
GU toxicity ≥ G1 was found for bladder V60 Gy ≥ 15%. 
 
Conclusion: In moderate hypofractionation in 30 fractions for 
prostate cancer, a prostate gland volume greater than 80 cc 
resulted as predictor of moderate acute GU toxicity. 
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Purpose or Objective: We have created and implemented in 
our department a new scheme of hypofractionated salvage 
volume modulated arc therapy with simultaneous integrated 
boost for patients with recurrence of prostate cancer (PCa) 
after radical prostatectomy (RP). The aims of our research 
are to evaluate toxicities and biochemical response rate. 
 
Material and Methods: Patients with recurrence of PCa after 
RP have been treated by hypofractionated (HF) salvage 
radiotherapy (SRT). Сharacteristics of HF radiotherapy were 
as follows: the prescribed dose to the regional lymphatic 
nodes was 46.8 Gy of 1.8 Gy per fraction, to the prostate bed 
- 61.1 Gy of 2.35 Gy per fraction in case of biochemical 
recurrence (BR) and if region of clinical recurrence (CR) was 
identified - 65 Gy of 2.5 Gy each, in 26 fractions with 
pretreatment imaging; VMAT (two arcs: CW (185°-175°), CCW 
(175°-185°) technology with SIB was used. Toxicities were 
scored using RTOG/EORTC Radiation Toxicity Grading. 
 
Results: 41 patients were treated by the HF SRT. Median 
follow-up was 22 months (10 - 30). Biochemical control rate – 
37 (90.2%) patients, locoregional control rate – 41 (100 %) 
patients. No grade 3 or greater acute toxicities were 
observed.  
 
Conclusion: We would like to suggest a new scheme of HF 
SRT with SIB in 26 fractions for patients with recurrence of 
PCa after RP. The toxicities and early biochemical response 
rates were comparable with conventional fractionation SRT.  
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Purpose or Objective: The Aim of this study is to evaluate 
PSA kinetics in men with intermediate and high risk prostate 
cancer treated with HDR brachytherapy boost in combination 
with external beam radiotherapy (EBRT) and short term 
androgen deprivation therapy (ADT). 
 
Material and Methods: Data from 134 consecutive patients 
treated with HDR brachytherapy boost in combination with 
external beam radiotherapy was extracted from a 
prospectively maintained database. All the patients had a 
minimum follow up of 4 years. Patients who were on 
androgen deprivation therapy for over 12 months were 
excluded from the analysis. After exclusion we had 95 
evaluable patients. All patients received either 17 Gy in 2 
fractions or 15 Gy in single fraction of HDR brachytherapy 
boost followed by external beam radiotherapy 37.5 Gy in 15 
fractions. 70% of patients received Androgen deprivation 
therapy (ADT) for less than or equal to 6 months, 15% 
received for 6- 12 months, and 15% received no hormones. 3-
6 months of ADT was given neoadjuvantly. Date of HDR boost 
was considered as time=0. Benign PSA bounce was defined as 
PSA rise of >0.2ng/ml followed by subsequent decline to pre 
bounce level. 
 
Results: Median follow-up was 4.3 years. At the time of 
median follow up the median PSA was 0.19. PSA bounce was 
seen in 32.6% (n=31). Magnitude of PSA bounce was <1ng/ml 
in 55% (n=17), 1-2ng/ml in 13% (n=4), >2ng/ml in 32% (N=10). 
In 16 out of 17 patients with a PSA bounce of <1ng/ml was 
due to a benign bounce. 50% of patients with a PSA bounce 
between 1-2ng/ml had a benign bounce and the remaining 
50% developed biochemical failure. In 9 out of 10 patients 
who had a PSA bounce of >2ng/ml subsequently developed a 
biochemical failure . Most common  
time for benign PSA bounce was between 6 and 18 months. 
 
 
 
Conclusion: PSA bounce is a common phenomenon which 
occurs in about a third of men who were treated with short 
term ADT in combination with HDR boost and EBRT. Benign 
PSA bounce tends to have a smaller magnitude of rise in PSA 
<1ng/ml. However patients who developed biochemical 
failure had PSA bounce of larger magnitude >2ng/ml. 
Investigators at the time of submission of the abstract are 
examining variables which predict PSA bounce. 
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Purpose or Objective: A retrospective analysis in 368 
consecutives organ confined prostate cancer (PC) patients 
has been made for evaluating the rates of haematuria, 
etiology and onset time. All these patients have been treated 
from September 2001 to December 2013 with different 
multimodality radical radiotherapy approaches: Intensity 
Guided Modulated radiotherapy (IGRT), Low dose rate 
brachytherapy (LDR BT) exclusively, LDR BT plus External 
radiotherapy (EBRT) or High dose rate Brachytherapy (HDR-
BT) plus EBRT. 
 
Material and Methods: Median age of the whole group was 
70,5 years (range 60-81y). Median PSA at diagnostic of the 
prostate cancer was 9.3 ng/ml (range 4,67-95 ng/ml). Median 
Gleason 6 (range 2-10). 20 patients (41,47%) had received 
IGRT radiotherapy treatment, 4 patients (8%) LDR BT, 10 
patients (21%) LDR plus EBRT and 14 patients (30%) HDR-BT 
plus EBRT. In 17 patients (35,4%) the complete pelvis (L5-S1) 
